Serum Fructosamine as a Preoperative Test
Serum fructosamine is NOT routinely recommended as a standard preoperative test according to established guidelines, but emerging evidence suggests it may be a valuable tool for assessing short-term glycemic control in diabetic patients when HbA1c is inadequate or when recent glucose variability is a concern.
Guideline Recommendations on Preoperative Glucose Testing
The established preoperative testing guidelines do not include fructosamine as a standard test. According to the 2013 American Family Physician guidelines, preoperative glucose testing should be based on clinical context, comorbid conditions, surgical risk, and medication use—not ordered routinely 1. The guidelines specifically state that random glucose testing in patients with known diabetes rarely alters perioperative management because it only reflects control over the past few hours 1.
For diabetic patients, the 2018 French perioperative guidelines recommend assessing glycemic control preoperatively using HbA1c levels and recent capillary blood glucose measurements, with a target blood sugar level <1.80 g/L (10 mmol/L) before intervention to decrease risk of death, infection, and prolonged hospital stay 2. Fructosamine is not mentioned in these established guidelines.
Why Fructosamine May Be Ordered Despite Guideline Absence
Short-Term Glycemic Control Assessment
Fructosamine reflects mean glycemic control over 2-3 weeks, compared to HbA1c which reflects 6-8 weeks 3. This shorter timeframe makes it responsive to recent changes in therapy and can identify patients with recent glycemic instability that HbA1c might miss 2.
Superior Predictive Value for Complications
Recent research demonstrates that fructosamine ≥292 μmol/L is associated with significantly higher risk of deep infection (adjusted OR 6.2), readmission (adjusted OR 3.0), and reoperation (adjusted OR 3.4) after total joint arthroplasty 4. In this same study, HbA1c ≥7% failed to show significant correlation with these outcomes 4.
In foot and ankle surgery, preoperative fructosamine was significantly higher (269.2 vs 247.2 μmol/L, p=0.029) in patients who developed complications within 90 days, and was found to be non-inferior to HbA1c in predicting postoperative complications 5.
Rapid Response to Glycemic Intervention
Animal model research suggests that 1,5-anhydroglucitol (another short-term marker) responds within 3 days to glycemic intervention, while HbA1c and fructosamine are lagging indicators 6. However, fructosamine still responds faster than HbA1c to therapeutic changes 3.
Specific Clinical Scenarios
Fructosamine may be particularly useful when:
- HbA1c is unreliable (hemoglobinopathies like sickle cell disease, recent transfusions, hemolytic anemia) 7
- Recent glycemic instability is suspected despite acceptable HbA1c 2
- Insulin-dependent patients who may have greater short-term glucose variability 8
- Detecting unrecognized diabetes or hyperglycemia in non-diabetic patients 4
Clinical Thresholds and Interpretation
The clinically significant threshold is fructosamine ≥292-293 μmol/L, which correlates with HbA1c of 7% 5, 4. Values above this threshold warrant:
- Consideration of surgical delay for optimization
- Enhanced perioperative glucose monitoring
- Aggressive perioperative glycemic management protocols
Important Caveats
- Fructosamine is not a guideline-recommended standard preoperative test and should not replace clinical judgment based on history, physical examination, and established markers 1
- It is most useful as an adjunct to, not replacement for, HbA1c in specific clinical scenarios
- The test is simple and inexpensive but requires laboratory capability 4
- 20% of patients may have elevated fructosamine despite normal HbA1c, identifying a hidden high-risk population 4
In practice, fructosamine should be considered for preoperative testing in diabetic patients undergoing orthopedic procedures (particularly joint arthroplasty or foot/ankle surgery), patients with suspected recent glycemic instability, or when HbA1c reliability is compromised—but it is not part of routine preoperative screening protocols.